Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients.
Abou-Jaoude
M M
MM
St-Georges Hospital, Beirut, Lebanon.
Ghantous
I
I
Najm
R
R
Afif
C
C
Almawi
W Y
WY
D000328:Adult; D000906:Antibodies / Q000097:blood; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D000077561:Daclizumab; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D013997:Time Factors
D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D008055:Lipids; D003404:Creatinine; D000077561:Daclizumab